A Phase 1, Open-Label Study to Assess the Relative Bioavailability of Two LY4064809 Formulations in Healthy Adult Participants
Latest Information Update: 28 Jan 2026
At a glance
- Drugs STX-478 (Primary)
- Indications Breast cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
Most Recent Events
- 23 Jan 2026 Status changed from not yet recruiting to recruiting.
- 21 Jan 2026 New trial record